Business Wire

ExOne Reveals Advanced InnoventPro Metal 3D Printer Concept, Offering All-New Features in Binder Jetting

Share

The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today debuted a concept rendering of the InnoventPro, a preview of the world’s most advanced entry-level binder jetting system for printing metals, ceramics and composites.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005243/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The InnoventPro (left) is an advanced entry-level metal 3D printer that rounds out ExOne's full family of production metal binder jetting systems, which includes the X1 25Pro (center) and the X1 160Pro (far right). ExOne is also introducing the X1D1 automated guided vehicle for efficient Industry 4.0 transport of heavy build boxes from 3D printing through final sintering operations. (Photo: Business Wire)

The InnoventPro will be a major upgrade of the Innovent+, the world’s best-selling metal binder jetting system since 2016. The InnoventPro will offer two new build sizes, a 3-liter and a 5-liter, with print speeds topping 700 cc/hour. The updated system is aimed at academics, researchers, and a full spectrum of manufacturers, from machine and MIM shops to high-volume producers, who want to produce metal parts quickly, affordably and sustainably.

“Customers around the world already love the Innovent+, and based on their feedback, we’re going to give them an updated entry-level system that’s bigger, faster and smarter than ever,” said John Hartner, ExOne CEO.

Siemens Digital Industries will serve as an Industry 4.0 collaboration partner on the production version of the machine, to be unveiled in the second half of 2021. An incentive program for the InnoventPro will be offered to customers who buy an Innovent+ prior to commercial availability of the new system. Learn more at www.exone.com/InnoventPro

Raising the bar in binder jetting

Binder jetting is a groundbreaking 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.

Binder jetting is a sustainable method of manufacturing that reduces material waste to less than 5%, saves energy by consolidating many assembled parts and processes into one, and can deliver end-use products that are 30-40% lighter — for more efficient cars, planes and military equipment.

Importantly, the new InnoventPro will feature the same recirculating printhead modules used on the X1 25Pro® and X1 160Pro metal 3D printers, allowing users to easily scale up from R&D to high-volume production.

The recirculating printhead also enables ExOne’s pioneering move to offer particulate binders as an option on a commercial binder jetting system. The ExOne research team has been 3D printing a variety of nanoparticles suspended in its binders for years.

All-New Class of NanoFuse Binders

First patented in 2018, with related patents pending worldwide, ExOne’s “inkjet-printable nanoparticle suspensions” are slated for commercial deployment in the InnoventPro. This all-new class of ExOne NanoFuse binders advances the field of binder jet 3D printing in critical ways.

Because nanoparticles fill in the interstices between powder bed particles and can bond at lower temperatures, they enable stronger green parts. In turn, this enables 3D printing of larger parts and finer features, delivering sharper corners and edges. These new binders can also improve the resolution and sinterability of high-demand metals, such as copper and aluminum.

Rick Lucas, ExOne CTO and VP, New Markets, said the InnoventPro and new NanoFuse binders show how ExOne continues to lead the way in commercial development of binder jetting.

“Just as the current Innovent+ served as the proving ground for our patented Triple ACT system, which now delivers industry-leading quality in metal binder jetting, the InnoventPro will offer groundbreaking new features in a commercial system,” Lucas said. “Our patented approach to 3D printing particulate inks in a print bed is opening new doors in binder jetting.”

ExOne’s patented Triple ACT is a critical advanced compaction technology that, depending on material, delivers industry-leading final part density of 97+%, dimensional tolerances in the range of <1%-2.5%, and high consistency, with part variation of just 0.3% across the print bed.

Triple ACT has been so effective that it has also sped up ExOne’s qualification of new materials. ExOne binder jet systems now process more than 20 metal, ceramic and composite materials, with single-alloy metals making up more than half of those offerings. NanoFuse binders are expected to expand that material range and improve sintering dynamics.

A webinar about NanoFuse will be held at 9 a.m. on Wednesday, Nov. 4. Details are available at https://tinyurl.com/NanoFuseWebinar.

About ExOne

ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sarah Webster
Global Marketing Director
724-516-2336
sarah.webster@exone.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye